Sign in

    Khalil Fenina

    Research Analyst at Goldman Sachs

    Khalil Fenina is an Equity Research Analyst at Goldman Sachs & Co. LLC, focusing on global investment research across publicly traded companies. Based at the firm's New York office, he began his tenure in June 2023 and plays a key role in delivering sector-specific equity analysis, including coverage of firms like HUTCHMED Limited. Fenina’s in-depth research contributions support portfolio management strategies for Goldman Sachs clients, though published rankings or third-party performance statistics are not publicly available. Details on his professional credentials such as securities licenses or regulatory registrations have not been found in public records.

    Khalil Fenina's questions to PTC THERAPEUTICS (PTCT) leadership

    Khalil Fenina's questions to PTC THERAPEUTICS (PTCT) leadership • Q4 2024

    Question

    Khalil Fenina, on behalf of Paul Choi, asked about the company's capital deployment plans for the remainder of the year, given its strong cash position and proximity to operational breakeven.

    Answer

    CEO Dr. Matthew Klein reiterated that the company's strong cash position was built without assuming European Translarna revenue, making any ongoing sales upside. He stated the capital is sufficient to reach cash flow breakeven without needing to raise additional funds and also allows for strategic business development to augment the portfolio.

    Ask Fintool Equity Research AI

    Khalil Fenina's questions to FIBROGEN (FGEN) leadership

    Khalil Fenina's questions to FIBROGEN (FGEN) leadership • Q3 2024

    Question

    Inquired about the proportion of patients who will receive PET imaging in the upcoming Phase 2 trial of FG-3246 and sought clarification on the company's revenue guidance for Roxadustat, specifically the discrepancy between China sales growth and overall net sales guidance and the role of deferred revenue.

    Answer

    The majority, but not all, of the 75 patients in the Phase 2 trial will be imaged with the PET agent due to the timing of the IND filing. The Q4 revenue guidance accounts for a potential accounting adjustment (increased deferred revenue) if the CIA indication is approved in Q4, which would lower recognized revenue for the period. The $12.5 million in Q3 was a release from deferred revenue, increasing Q3's reported revenue.

    Ask Fintool Equity Research AI

    Khalil Fenina's questions to FIBROGEN (FGEN) leadership • Q3 2024

    Question

    Khalil Fenina of Goldman Sachs asked if all 75 patients in the upcoming FG-3246 Phase 2 monotherapy trial would be imaged with the FG-3180 PET agent. He also sought clarification on FibroGen's Q4 revenue guidance for roxadustat, questioning the implied sequential decline and the nature of a $12.5 million deferred revenue adjustment.

    Answer

    CEO Thane Wettig responded that the majority, but not all, of the 75 patients would receive the PET imaging agent due to staggered IND filings for the drug and the agent. CFO Juan Graham explained the revenue guidance accounts for a potential accounting adjustment; if the CIA indication is approved in Q4, accounting rules would require deferring more revenue, thus lowering the recognized figure for the quarter. He confirmed the $12.5 million was a release from deferred revenue, which increased Q3's reported revenue.

    Ask Fintool Equity Research AI